DONNA ROY GROGAN - 02 Jan 2025 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Director
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
02 Jan 2025
Net transactions value
+$13,751
Form type
4
Filing time
03 Jan 2025, 16:08:34 UTC
Previous filing
02 Oct 2024
Next filing
03 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Award $13,751 +3,757 +13% $3.66 32,699 02 Jan 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
F2 The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 2, 2025.